Abstract
The reaction of K2PtCl4 with anticancer-alkylating agent mechlorethamine hydrochloride (CH3NH(C2H4Cl)2 x HCl = HN2xHCl), in the molar ratio 1 : 2, affords the complex [H2N2]2[PtCl4]. In vitro antimicrobial and lipoxygenase inhibitory activities of the complex and its precursor were evaluated. Antimicrobial activity of the HN2xHCl and [H2N2]2[PtCl4] complex was investigated against 29 species of microorganisms. Testing is performed by microdilution method. Minimum inhibitory concentration (MIC) and minimum microbicidal concentration (MMC) have been determined. The difference between antimicrobial activity of precursor and corresponding platinum(II) complex is noticed and the activity of the precursor was higher. Tested compounds demonstrated the high and significant antifungal activity and low to moderate antibacterial activity. It was shown that the gram-positive bacteria were more sensitive than the gramnegative. UV absorbance-based enzyme assays were performed with HN2xHCl and [H2N2]2[PtCl4] complex, in order to evaluate their in vitro inhibitory activity of soybean lipoxygenase (LOX), also. Assay with LOX showed significantly greater inhibitory activity of the complex, than the precursor.
Keywords: Antibacterial activity, Antifungal activity, Mechlorethamine hydrochloride, Platinum(II) complex, Soybean lipoxygenase inhibition, DNA, RNA, proteins, purine bases, histidine
Medicinal Chemistry
Title:Biological Evaluation of Mechlorethamine-Pt(II) Complex, Part II: Antimicrobial Screening and Lox Study of the Complex and its Ligand
Volume: 8 Issue: 5
Author(s): Ivana D. Radojevic, Zorica D. Petrovic, Ljiljana R. Comic, Dusica Simijonovic, Vladimir P. Petrovic and Dimitra Hadjipavlou-Litina
Affiliation:
Keywords: Antibacterial activity, Antifungal activity, Mechlorethamine hydrochloride, Platinum(II) complex, Soybean lipoxygenase inhibition, DNA, RNA, proteins, purine bases, histidine
Abstract: The reaction of K2PtCl4 with anticancer-alkylating agent mechlorethamine hydrochloride (CH3NH(C2H4Cl)2 x HCl = HN2xHCl), in the molar ratio 1 : 2, affords the complex [H2N2]2[PtCl4]. In vitro antimicrobial and lipoxygenase inhibitory activities of the complex and its precursor were evaluated. Antimicrobial activity of the HN2xHCl and [H2N2]2[PtCl4] complex was investigated against 29 species of microorganisms. Testing is performed by microdilution method. Minimum inhibitory concentration (MIC) and minimum microbicidal concentration (MMC) have been determined. The difference between antimicrobial activity of precursor and corresponding platinum(II) complex is noticed and the activity of the precursor was higher. Tested compounds demonstrated the high and significant antifungal activity and low to moderate antibacterial activity. It was shown that the gram-positive bacteria were more sensitive than the gramnegative. UV absorbance-based enzyme assays were performed with HN2xHCl and [H2N2]2[PtCl4] complex, in order to evaluate their in vitro inhibitory activity of soybean lipoxygenase (LOX), also. Assay with LOX showed significantly greater inhibitory activity of the complex, than the precursor.
Export Options
About this article
Cite this article as:
D. Radojevic Ivana, D. Petrovic Zorica, R. Comic Ljiljana, Simijonovic Dusica, P. Petrovic Vladimir and Hadjipavlou-Litina Dimitra, Biological Evaluation of Mechlorethamine-Pt(II) Complex, Part II: Antimicrobial Screening and Lox Study of the Complex and its Ligand, Medicinal Chemistry 2012; 8 (5) . https://dx.doi.org/10.2174/157340612802084315
DOI https://dx.doi.org/10.2174/157340612802084315 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
6,7-Dimethoxyquinazolines as Potential Cytotoxic Agents: Synthesis and in vitro Activity
Letters in Drug Design & Discovery System Level Meta-analysis of Microarray Datasets for Elucidation of Diabetes Mellitus Pathobiology
Current Genomics Meet Our Editorial Board Member: Major Academic/Scientific Achievements
Current Cancer Drug Targets Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes
Current Drug Targets Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Regulation of Cell Death and Survival by Resveratrol: Implications for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Antiangiogenic Therapies in Non-Hodgkin's Lymphoma
Current Cancer Drug Targets BELFAST Centenarians: A Case of Optimal Cardiovascular Risk?
Current Pharmaceutical Design Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Meet Our Editorial Board Member
Current Cancer Drug Targets Targeting Interleukin (IL) 5 for Asthma and Hypereosinophilic Diseases
Recent Patents on Inflammation & Allergy Drug Discovery An Overview on Global Trends in Nanotechnological Approaches for Alzheimer Therapy
Current Drug Metabolism Synthesis and Evaluation of Haloacetyl, α-Bromoacryloyl and Nitrooxyacetyl Benzo[b]furan and Benzo[b]thiophene Derivatives as Potent Antiproliferative Agents Against Leukemia L1210 and K562 Cells
Letters in Drug Design & Discovery Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy
Current Cancer Drug Targets Mechanisms of Focal Adhesion Kinase Regulation
Current Cancer Drug Targets Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets The Significance of Renal Function in Response to Cardiac Resynchronisation Therapy – A Piece of a Much Larger Puzzle
Current Vascular Pharmacology Psychopathological Behaviour and Cognition in Morbid Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Killing the Messenger: Antisense DNA and siRNA
Current Drug Targets